Publication Name	World Journal of Gastrointestinal Pharmacology and Therapeutics
Manuscript ID	33443
Country	United States

Received	2017-02-09 09:28
Peer-Review Started	2017-02-09 17:01
To Make the First Decision	2017-03-13 10:33
Return for Revision	2017-03-17 11:37
Revised	2017-05-14 22:47
Second Decision	2017-06-02 03:03
Accepted by Journal Editor-in-Chief	2017-06-02 10:12
Accepted by Company Editor-in-Chief	2017-06-07 07:24
Articles in Press	2017-06-07 07:24
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2017-07-26 07:16
Publish the Manuscript Online	2017-08-01 00:23

ISSN	2150-5349 (online)
Open Access	This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2017. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Editorial
Article Title	Strategies for overcoming anti-tumor necrosis factor drug antibodies in inflammatory bowel disease: Case series and review of literature
Manuscript Source	Invited Manuscript
All Author List	Mansi M Kothari, Douglas L Nguyen and Nimisha K Parekh
Funding Agency and Grant Number
Corresponding Author	Mansi M Kothari, MD, Fellow, Department of Medicine (Gastroenterology), University of California-Irvine, UC Irvine Medical Center, 101 The City Drive S, Orange, CA 92868, United States. mmkothar@uci.edu
Key Words	Inflammatory bowel disease; Adalimumab; Anti-tumor necrosis factor; Infliximab; Therapeutic drug monitoring; Drug antibody; Antidrug antibodies; Dose escalation
Core Tip	One of the main challenges of anti-tumor necrosis factor use in inflammatory bowel disease is immunogenicity, or the immune-mediated formation of drug antibodies. Therapeutic drug monitoring allows for measurement of serum drug levels and antidrug antibodies. Previously it was thought that antibody formation was indication to switch to an alternate agent; however, more recent literature, which we review in this article, suggests that a low level of antidrug antibodies can be overcome by dose escalation of the biologic drug and/or addition of an immunomodulator. We describe a small case series of patients in whom this strategy was used, in conjunction with therapeutic drug monitoring, with some success.
Publish Date	2017-08-01 00:23
Citation	Kothari MM, Nguyen DL, Parekh NK. Strategies for overcoming anti-tumor necrosis factor drug antibodies in inflammatory bowel disease: Case series and review of literature. World J Gastrointest Pharmacol Ther 2017; 8(3): 155-161
URL	http://www.wjgnet.com/2150-5349/full/v8/i3/155.htm
DOI	http://dx.doi.org/10.4292/wjgpt.v8.i3.155

Full Article (PDF)	WJGPT-8-155.pdf
Full Article (Word)	WJGPT-8-155.doc
Manuscript File	33443-Review.docx
Answering Reviewers	33443-Answering reviewers.pdf
Audio Core Tip	33443-Audio core tip.mp3
Conflict-of-Interest Disclosure Form	33443-Conflict-of-interest statement.pdf
Copyright License Agreement	33443-Copyright assignment.pdf
Peer-review Report	33443-Peer-review(s).pdf
Journal Editor-in-Chief Review Report	33443-Journal editor-in-chief review report.pdf
Scientific Misconduct Check	33443-Scientific misconduct check.pdf
Scientific Editor Work List	33443-Scientific editor work list.pdf